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Abstract
Introduction Hyperthermia therapy (HT) is a recognized treatment modality, that can sensitize tumors to the effects of 
radiotherapy (RT) and chemotherapy by heating up tumor cells to 40–45 °C. The advantages of noninvasive inductive mag-
netic hyperthermia (MH) over RT or chemotherapy in the treatment of recurrent/progressive glioma have been confirmed 
by several clinical trials. Thus, here we have conducted a systematic review to provide a concise, albeit brief, account of the 
currently available literature regarding this topic.
Methods Five databases, PubMed/Medline, Embace, Ovid, WOS, and Scopus, were investigated to identify clinical studies 
comparing overall survival (OS) following RT/chemotherapy versus RT/chemotherapy + MH.
Results Eleven articles were selected for this systematic review, including reports on 227 glioma patients who met the study 
inclusion criteria. The papers included in this review comprised nine pilot clinical trials, one non-randomized clinical trial, 
and one retrospective investigation. As the clinical trials suggested, MH improved OS in primary glioblastoma (GBM), 
however, in the case of recurrent glioblastoma, no significant change in OS was reported. All 11 studies ascertained that no 
major side effects were observed during MH therapy.
Conclusion Our systematic review indicates that MH therapy as an adjuvant for RT could result in improved survival, com-
pared to the therapeutic outcomes achieved with RT alone in GBM, especially by intratumoral injection of magnetic nano-
particles. However, heterogeneity in the methodology of the most well-known studies, and differences in the study design 
may significantly limit the extent to which conclusions can be drawn. Thus, further investigations are required to shed more 
light on the efficacy of MH therapy as an adjuvant treatment modality in GBM.
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Introduction
With a recorded number of 296,851 new cases globally, 
the year 2018 concluded with 241,037 deaths due to glio-
blastoma, indicating an annual mortality rate of 81.19% 
[1]. Encompassing 47.7% of all malignant brain tumors, 
glioblastoma is an insidious disease of poor prognosis, 
allowing roughly 5.6% of patients to meet their 5 year 
survival following diagnosis, according to the statistical 
report of the Central Brain Tumor Registry of the United 
States (CBTRUS) [2]. Nearly unchanged through the last 
few decades, the standard therapeutic approach to glio-
blastoma, based on the World Health Organization (WHO) 
guidelines, consists of surgical resection, radiation therapy 
(RT), and chemotherapy [3, 4].
A debilitating disease of the central nervous system 
with an aggressive behavior, glioblastoma has long been 
challenging mankind in terms of treatment [5]. Treatment 
is palliative and non-curative in most cases, providing only 
a short interval for patients, that usually does not exceed 
24 months [6]. Due to the lack of a definitive treatment, 
alternative therapeutic modalities such as multimodal syn-
ergistic therapy have been developed [7, 8]. An effective 
combination of different conventional treatments, multi-
modal synergistic therapy integrates several modalities 
into an adjuvant therapy, such as hyperthermia, providing 
enhanced therapeutic effects compared to that of a singular 
treatment [9].
In hyperthermia, the therapeutic goal is to deliver the 
predetermined minimum effective dose to more than 90% 
of the target region [10]. The total thermal energy deliv-
ered to the site is measured with a well-recognized for-
mula, in which the duration of exposure is normalized to 
the base effective temperature of 43 °C (CEM43) [11]. 
Magnetic hyperthermia therapy (MHT), a localized form 
of hyperthermia, adopts magnetic mediators or agents to 
convert the electromagnetic energy into heat, which is gen-
erated by an alternating magnetic field (AMF) in the first 
place [12]. The energy conversion is believed to be medi-
ated through hysteresis losses, Brownian and Neel relaxa-
tion, a process in which frictional heating is produced by 
the physical rotation of magnetic particles [12]. To per-
form magnetic hyperthermia, a magnetic agent, along with 
a solenoid/head coil and thermocouples are required for 
generating an alternating magnetic field and measuring the 
temperature, respectively [13].
In spite of the non-specific regional application of AMF 
to the body, one can still achieve the localized heating 
of any desired region through delivering magnetic agents 
directly to the tumor site by means of targeted systemic 
delivery or intratumoral administration [12]. The recent 
development of different magnetic mediators, including 
millimeter and micrometer-scaled ferromagnetic alloy 
thermoseeds and metallic stents for interstitial implant-
based hyperthermia, and magnetic nanoparticles (MNPs) 
for intracellular hyperthermia, has paved the way for 
clinical application of this technique [14]. Through the 
last few years, great steps have been taken in the devel-
opment of MNPs [15]. Deeply-located magnetic agents 
inside tissues can be activated at organs by MHT at cer-
tain frequencies (f) and field (H) conditions, that are not 
harmful to the body (H × f ≤ 5 × 108 A/ms) [16]. These 
agents release heat upon being exposed to an alternating 
magnetic field (AMF) of appropriate amplitude and fre-
quency. The resulting heat leads to apoptotic or necrotic 
cell death in the tumor site, thus, decreasing the viability 
of tumor cells [9].
After demonstrating that magnetic particles could be 
selectively delivered to the tumor site and activated under 
an AMF to generate heat, Gilchrist et al. proposed the con-
cept of magnetic hyperthermia (MH) for the first time in the 
1960s [17]. Following three decades of exploration, the first 
clinical trial on MH through thermoseeds was conducted 
in Japan by Kida et al., who had investigated the treatment 
of brain cancer, and achieved promising therapeutic results 
[18]. Accordingly, one might expect the advent of high 
selectivity and enhanced heating homogeneity in the light 
of magnetic nanoparticle hyperthermia (MNH). In the mean-
time, the first clinical trial on MNP-based therapy against 
brain tumors, called  NanoTherm®therapy (MagForce, Ger-
many) [19], is in the second phase of clinical trial [20].
It is arguable that a well-evidenced combination of mag-
netic hyperthermia with the current conventional antitumor 
therapies could bring remarkable advantages to the treat-
ment of glioblastoma. To our knowledge, there has never 
been a systematic review published on the effects of MH on 
the survival of patients with glioblastoma. Thus, we con-
ducted a systematic review on the pertinent clinical trials 
in an attempt to summarize the evidence on the relationship 
between magnetic hyperthermia therapy and glioblastoma 
treatment (PICOS is detailed in Supplement 1).
Methods
The present study follows the PRISMA statement for trans-
parent and comprehensive reporting of methodology and 
results [21].
Search strategy
We searched the following databases without restrictions 
on the language or date of publication, and humans were 
defined as the subject for this review:
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PubMed/MEDLINE, Web of Science, Ovid, Excerpta 
Medica Database (Embase), and Scopus, updated as of 
June 2020. The PubMed search strategy is explained in 
Supplement 2.
Searching Other Resources:
We searched for the currently recruiting trials on the 
websites of Clinical Trials, World Health Organization 
(WHO), and International Clinical Trials Registry Plat-
form (ICTRP).
Conference abstracts and proceedings from the last five 
years were looked for on the database of the American 
Society of Clinical Oncology (ASCO; supplements of 
Neuro-Oncology), and the International Psycho-Oncology 
Society (IPOS; The main journals in the field of neuro-
oncology: Journal of Neuro-Oncology, Journal of Clinical 
Oncology, Thermal Medicine (Japanese Journal of Hyper-
thermic Oncology)). Publications from the last year that 
were not identified through the electronic search, were 
manually explored. We also manually sought relevant 
reference lists of important review articles, and that of 
the included articles. In addition, beyond major scientific 
databases, we also searched Google Scholar.
Protocol and registration code: PROSPERO 2020 
CRD42020206990 [22].
Initial screening using eligibility criteria
The present study only included papers that met the fol-
lowing criteria: (1) clinical trials (CTs); (2) application of 
magnetic hyperthermia intervention as adjuvant therapy 
induced via radiofrequency coil; (3) inclusion of patients 
with primary or recurrent gliomas with or without prior 
history of surgery, radiotherapy or chemotherapy; (4) 
providing overall survival (OS) data until the death or 
last follow-up of patients; and (5) inclusion of an adult 
patient population (≥ 18 years of age). Articles that rep-
resented over 50% of tumor types pertaining to the CNS 
were excluded. Editorials, letters, reviews, book series and 
non-human studies were also excluded. In addition, studies 
that had not published a full manuscript (such as confer-
ence presentations and abstract-only publications) were 
excluded, as well.
Candidate papers extracted from the earlier mentioned 
databases were reviewed for their relevance to the issue by 
means of Endnote (1095 papers). Duplicated articles were 
screened for and consolidated on initial review. Titles and 
abstracts of retrieved articles were first screened by two inde-
pendent authors (S. Shievalilou and A.J. Esfahani). After-
wards, the same two authors read the full text of potentially 
suitable articles separately. Discrepancies were resolved by 
discussion (see Fig. 1 for PRISMA flow diagram of the pre-
sent study).
Data extraction
We adopted a systematic data extraction tool for collection 
of the following:
Every paper considered for inclusion in this study was 
investigated for the following data: (1) general informa-
tion: author name, year of publication, country of origin; 
(2) clinical data including: number of patients, age and gen-
der, type of brain tumor, intervention details (summary of 
intervention and magnetic hyperthermia techniques used) 
and follow-up period; and (3) treatment outcomes including: 
median overall survival in months, side effects and mortal-
ity rates. The final verdict upon the inclusion of the selected 
papers was given by two reviewers (S. Shirvalilou and A.J. 
Esfahani). Both reviewers extracted data from each manu-
script, while the third reviewer (S. Khoei) evaluated this data 
for accuracy and cohesiveness, independently.
A meta-analysis was not performed due to the heteroge-
neity in treatment regimens (e.g., monotherapy vs various 
combination regimens), the small sample size and study 
design (e.g., starting time-point for defining OS).
Risk of bias assessment
Risk of bias for every investigation included was assessed 
following the guidelines of Cochrane Collaboration Hand-
book [23]. Two authors (S. Shirvalilou and R. Sheervalilou) 
independently evaluated the risk of study bias. Any discrep-
ancies in the results or the quality of studies were resolved 
in consensus with the third author (S. Khoei).
Results
Search strategy results
Following the search strategy described above, a total of 
1080 records were identified, including 78 citations from 
PubMed, 445 from Embase, 251 from Ovid, 299 from Web 
of Science, 7 from Scopus, and 15 from other sources (e.g., 
international conferences). After the exclusion of duplicates, 
902 records were screened. Initial assessment of titles and 
abstracts resulted in exclusion of 858 records, since they 
did not meet the inclusion criteria for our paper. Forty-four 
records were identified as potentially suitable for assessment 
through full-text reviewing. Of these, nine were excluded, 
as they did not report clinical trials, fourteen were excluded 
due to the unavailability of their full-text and lack of suffi-
cient primary data, three were ruled out for being editorials 
and review articles, five clinical trials were put aside for 
not providing any relevant data on survival of patients, and 
two were eliminated for not reporting any findings regard-
ing magnetic hyperthermia. Following this process, 11 
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remaining papers were included into this systematic review. 
Ten articles were in English [19, 24–32], and one was in 
Japanese [33]. The search strategy is summarized in Fig. 1.
Included studies and participant details
Full details of 11 eligible studies are summarized in Table 1. 
Out of the 11 clinical trials assessed, 6 were phase I trials 
[19, 24–26, 29, 33], 3 were mixed phase I and phase II [27, 
30, 31], and 2 were phase II trials [28, 32]. Most studies 
were prospectively designed. A total of five were conducted 
in the United States [25, 27, 29–31], four in Germany [19, 
24, 28, 32], and two in Japan [26, 33]. Upon assessment of 
the papers, significant heterogeneity was detected in patient 
characteristics including tumor status, Karnofsky perfor-
mance scale (KPS), pretreatment modalities, treatment 
protocol, and performance status. Based on the incorpora-
tion of magnetic hyperthermia, all studies included in this 
review can be divided into three subgroups; MH with cath-
eter implantation (1990–1994) [25, 27, 29–31], MH with 
thermo-seed implantation (1991–1993) [26, 33], and MH 
with implantation of magnetic nanoparticles (2007–2019) 
[19, 24, 28, 32].
A total of 262 patients were investigated in the 11 studies 
included here. Of the 237 cases reported in 10 articles [19, 
24, 26–33], the majority of patients were treated for recur-
rent disease (n = 122, 51.5%), while 105 patients (44.3%) 
received treatment for primary disease. Last but not least, 
10 patients (4.2%) were treated for metastatic disease. A 
total of 202 patients were diagnosed with glioma (86.6% 
glioblastoma and 13.3% astrocytoma). The age or sex of the 
patients were not reported in 2 studies [25, 33]. Considering 
the available data (n = 20), the age range was 21–79, and 
53% of patients were male.
Treatment characteristics
Most patients had already been extensively treated for their 
disease (surgery and radiotherapy with/without chemo-
therapy) on the areas in their body that were going to be 
treated with MH. During MH therapy, patients received a 
median external RT dose of 49.2 Gy (range 30–70) [24], 
brachytherapy (88.7 Gy, range 20.3–151 Gy) [27], external 
RT with brachytherapy (26–41 Gy) [25, 29, 31], external 
RT combined with chemotherapy [19, 26, 32, 33], or exter-
nal RT (48.4 Gy, range 41–50.4 Gy) with brachytherapy 
Fig. 1  Flow chart of publication 
search and selection
Records idenfied through (n=1080)
PubMed/Medline (n=78), Embace (n=445)
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er to the Editor
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Table 1  Characteristics of the included studies
No Author Country Total 
patients
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(32.7 Gy, range 13.9–50 Gy) combined with chemotherapy 
[30] (Table 1).
For magnetic hyperthermia, plastic catheters were used 
for implantation of ferromagnetic nickel-silicon alloys into 
tumors in five multiple places studies [25, 27, 29–31], Fe-Pt 
alloy thermo-seeds in two studies [26, 33], magnetic fluid 
containing 112 mg/ml iron oxide nanoparticles in three stud-
ies [19, 28, 32], and 20 mg/kg magnetic fluid in one study 
[24]. After implanting magnetic particles, hyperthermia was 
induced with alternating magnetic coil. In all investigations, 
MT therapy had an average duration of 60 min. Temperature 
during MH therapy was measured with invasive methods in 
all studies. These investigations, however, failed to precisely 
report the type of thermometry equipment, and the number 
of temperature sensors (Table 1). The tumor temperature in 
the MH session was between 38 and 43.7 °C [27, 33], or 42 
and 49 °C [19, 24–26, 28–31]. In one investigation, tumor 
temperature was reported 49.5 to 65.6 °C [32]. Hyperther-
mia was usually performed once or twice a week, however, 
two studies administered MH therapy two or three times a 
week [26, 33]. In most trials, the first course of MH was 
given 2 to 4 weeks following external RT (before brachy-
therapy), and a second course of MH followed immediately 
after disposing of the radioactive sources [25, 29–31]. In an 
investigation by Mack et al., 43 patients were treated with 
hyperthermia before the catheters were loaded with 92Ir, and 
17 patients received additional treatment after the radioac-
tive sources were unloaded [27]. Certain trials adopted two 
treatments per week [19, 24, 26, 33]. In one study, stereo-
tactic radiotherapy was initiated immediately before or after 
intratumoral thermotherapy [28]. One investigation failed to 
report the time interval between HT and RT [32] (Table 1).
Outcomes
Due to the heterogeneity and small sample sizes in these 
studies, we were not able to categorize them, and perform 
a statistical analysis on the available data. Thus, a brief 
description of each investigation is provided later in this 
manuscript. Accordingly, we considered two main out-
comes: overall survival (OS) and mortality rate.
Overall survival
All 11 studies reported certain rates for OS. In this regard, 
the survival time here is given in months, starting from the 
day of re-treatment and diagnosis for patients with recur-
rent gliomas and primary untreated tumors, respectively. 
The majority of investigations were observational. One study 
reported hazard ratio (HR) as an index of patient mortality 
[31]. As for the measure of survival, two papers opted to 
report Kaplan Meier (KM) survival outcomes [28, 31]. One 
particular investigation indicated the survival advantage of a 
combination of IB (RT and brachytherapy) and IT (magnetic 
hyperthermia) over IB alone [31]. Stea et al., suggested that 
the median survival in patients with primary tumors (n = 25, 
23.5 months) for the IT group was significantly longer than 
patients treated with IB (n = 37, 13.5 months, P = 0.013). 
As for the patients with recurrent tumors, the estimated 
12-month survival probability was 0.23 for those treated 
with IT (n = 8, 95% CI = 0.0–0.46), that was not statistically 
different from the 0.25 value measured for patients treated 
with IB (n = 13, 95% CI = 0.0–0.55, P = 0.62) [31]. Maier-
Hauff et al., used historical controls from previous investiga-
tions to compare their results. According to their study, the 
median survival for recurrent glioma patients treated with 
RT and chemotherapy (temozolomide) combined with MH 
was 13.4 months, compared to the 6.2 months in patients 
who had received RT and chemotherapy, indicating a signifi-
cant difference [31]. Seven of the 11 studies reported posi-
tive effect of MH therapy on survival, however, they did not 
provide a direct comparison between therapeutic outcomes 
[19, 24–27, 29, 30].
Patient mortality was clearly defined in almost all of 
the studies. However, one paper did not clearly deline-
ate the patient follow-up time. Though, even among the 
Table 1  (continued)
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investigations that reported the patient follow-up time, it var-
ied majorly from 3 to 47 months. In 10 reported studies con-
ducted on a total of 218 patients, 164 patients (75.2%) died 
after treatment with hyperthermia throughout the follow-up 
time (3 to 47 months) [19, 24–26, 28–33]. A comprehensive 
summary and analysis of each study is presented in Table 2.
Thermal toxicity
All 11 studies reported that no major side effects were 
observed during MH therapy. All patients who had devel-
oped major (e.g., seizures, cerebral edema) or minor 
adverse effects (e.g., sweating up to grade 1, fluctuations 
in blood pressure, motor disturbances and transient brain 
edema) recovered perfectly without long-term complica-
tions. In two cases of magnetic hyperthermia with catheter 
implantation, migration of the implant (n = 1) and massive 
hemorrhage at the site of the implant (n = 2) were reported 
[26, 33]. In three studies, tissue samples were collected 
from 11 patients after receiving MH treatment. Kida et al., 
reported that in all 11 cases, a clear microscopic necro-
sis at the periphery of the implanted thermo-seeds was 
confirmed. Tumor cells were detected in 3 cases within 
the necrotic area [33]. Two investigations revealed that 
the majority of the nanoparticles had aggregated in the 
peripheral areas of the localized necrosis within the tumor 
[24, 32].
Risk of bias of the included studies
The results drawn from the quality assessment of these clini-
cal investigations are presented in Fig. 2. All components of 
the Cochrane Collaboration’s tool were adopted for assessing 
the risk of bias [23]. Blinding of outcome assessment was 
not performed for any of the endpoints. Incomplete outcome 
data were separately assessed for survival (essential param-
eters), mortality and toxicity (non-essential parameters). A 
high risk of attrition bias was detected, that was attributed 
to the incomplete outcome assessment for survival in several 
papers. Since the study designs had not been closely con-
trolled, we determined a high risk of bias due to the lack of 
blinding in all studies. The majority of bias types found in 
these studies lay within the inherent study design.
Table 2  Main results of the included studies
No. Author OS (months), median (range) Mortality (%) Treatment-related complications
in follow up time
1 Stea [29] Primary: (7–19)/recurrent: (1.5–9) 75.58 Transient neurologic complications (14)
focal seizures (3), hydrocephalus (1), cerebral edema 
(2)
2 Kida [33] Primary: (7 day–7 month)
Metastatic: (2 day–7 month)
81.81 Massive hemorrhage (2)/vasodilation (9), swelling (1)
3 Kobayashi [26] Primary: (1–21)/metastatic: (3–19) 60 Migration of the implant (1)/intratumoral hemorrhage 
(1)
4 Iacono [25] 12–39 month 88 Transient neurologic complications (5)
Focal seizures (5), cerebral edema (1)
5 Stea [30] Primary: 18.5 (2.25–43.61)
Recurrent: 5.8 (28 day–15.15 month)
57.14 Transient neurologic complications (4)
Focal seizures (6), hydrocephalus (1)
Pneumoencephalos (1)
6 Mack [27] 8 (1–53) – –
7 Stea [31] MH (primary): 23.5
Control (primary):13.5: (P = 0.013)
MH (recurrent): 12
Control (recurrent):12: NS
81.81 Focal seizures (11), cerebral edema (11)
Pulmonary embolus (2)
8 Maier-Hauff [19] Primary: (3–8.4)/recurrent: 7.6 (4.1–28) 92.85 Fluctuations in blood pressure (1)
Transient neurologic complications (1)
9 Van Landeghem [32] Primary: 2.1/recurrent: 7.9 100 Transient neurologic complications (3)
10 Maier-Hauff [28] Recurrent: 13.9 (10.9–16.8) 79.60 Transient neurologic complications (9), focal seizures 
(15)
tachycardia (12), motor disturbances (14), headaches 
(9)
fluctuations in blood pressure (10), sweating up to 
grade 1 (33)
11 Grauer [24] Recurrent: 8.1 (2.8–29.1) 83.33 Transient neurologic complications (6)
Sweating up to grade 1 (6)
426 Journal of Neuro-Oncology (2021) 152:419–428
1 3
Discussion
Combination of RT with hyperthermia, as some clinicians 
suggest, can be a promising modality for treatment of malig-
nancies, with an emphasis on local and extracranial control 
of the ongoing disease, that may actually improve the OS. 
However, such strategy is not supported by solid evidence. 
The present work is the first rigorous systematic review to 
have assessed the effectiveness and toxicity of magnetic 
hyperthermia in combination with radiotherapy or chemo-
therapy in the treatment of gliomas. To our knowledge, no 
papers have been published on this issue to date. However, 
the articles included in this systematic review mostly had 
reported data from patients with primary/recurrent glioma 
from glioblastoma (86.6%) and astrocytoma (13.3%), there-
fore, these findings cannot be generalized to patients with 
other brain malignancies. Historically, the literature suggests 
the emergence of a trend toward favoring magnetic type of 
radiofrequency hyperthermia, which is being explored by an 
increasing number of investigations to improve survival in 
advanced cancers [13].
In our list, three devices in 11 trials were intended for 
clinical application. In studies conducted in the USA, mag-
netic field coils (80–100 kHz and 1500–2000 A/m) and 
nickel-silicon thermo-seeds [25, 27, 29–31] were used, 
whereas the Japanese opted for magnetic induction coil 
(240 kHz, 1.65 kA/m) and Fe-Pt alloy seeds [26, 33], 
and the German chose magnetic induction coil (100 kHz, 
2.5–18 kA/m) and aminosilane coated superparamagnetic 
iron oxide nanoparticles (MagForce Nanotechnologies 
AG, Berlin, Germany) [19, 24, 28, 32]. In seven studies, 
toxicity due to catheter or thermo-seed implantation was 
attributed to migration of the implant or massive hemor-
rhage of the implant [25–27, 29–31, 33]. However, no such 
complications were reported in the other 4 investigations, 
that had used nanoparticle implants [19, 24, 28, 32].
The measured temperature during HT strongly depends 
on the type and extent of thermometry, and the tissue on 
which the technique is applied [34]. In all 11 studies, inva-
sive thermometry was adopted to monitor the temperature 
of the tumor site during hyperthermia sessions. Thermo-
couple probes (Copper-constantan, Manganin-constantan, 
French catheter) [19, 24, 26–28, 33] and fiberoptic ther-
mometry probes [25, 32] were used for thermometry. In 
3 investigations, two methods were used simultaneously 
to control the temperature[29–31]. Optimal temperature, 
albeit rarely achieved, ranged from 41 to 43 °C, as men-
tioned in all papers. On the other hand, the maximum tem-
perature achieved was often higher than the pre-specified 
allowed maximum limit, which ranged from 43 to 65.6 °C. 
This implicit heterogeneous temperature distribution 
resulted in a large variation between the maximum allowed 
temperatures attained by different institutes. The ESHO 
guidelines for superficial hyperthermia quality assurance, 
which has been published recently, might help to reduce 
such variation among institutes. According to these guide-
lines, one should aim for a T90 > 40 °C and T50 > 41 °C 
to locally maintain control over the tumor, with maximum 
temperatures of 43–45 °C [35]. Therefore, uniform tem-
perature distribution and proper monitoring is one of the 
inherent limitation of this method.
Despite the direct effect of the temperature and thermal 
dose of HT in the ultimate quality of treatment, these stud-
ies often failed to report such parameters, and thus, did 
not point out any specific relationship between the ther-
mal dose and therapeutic outcome. Only one study, led by 
Maier-Hauff, managed to report that no correlations were 
Fig. 2  Quality assessment of 
clinical studies was performed 
with use of the Cochrane Col-
laboration’s tool for assessing 
risk of bias [24]. + low risk 
of bias; − high risk of bias; ? 
unclear risk of bias
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found between tumor size, location, or treatment tempera-
tures with either OS or side effects [28].
The treatment has been deemed safe for both newly-
diagnosed patients and individuals with recurrent glioblas-
toma. Though, the clinical findings regarding the efficacy 
of this modality remains contentious. The greater propor-
tion of the studies included in this review were observa-
tional, except for the investigation by Stea et al., where 
patients were classified prospectively into two exposure 
groups (RT vs RT and MH) [31]. Almost none of the 
patients in these studies were randomly assigned to differ-
ent groups. These investigations also failed to match cer-
tain variables, e.g., ethnicity and comorbidities, between 
the groups, which might have led to remarkable differences 
in clinical outcomes reported for each group. Despite such 
limitations, we opted for an optimistic approach toward 
magnetic hyperthermia with nanoparticle implantation, as 
the majority of studies have suggested a positive associa-
tion between OS and MH in glioma. However, in spite of 
this optimism, hyperthermia should be approached with 
caution, i.e., proper selection of patients, skillful applica-
tion of intracranial injection techniques, and thermometry 
probes. It is highly imperative to minimize post-treatment 
neurological sequelae, that may counteract any potential 
benefits to the survival of patients. While further rand-
omized clinical trials are underway, one ought to rely on 
available data and rational clinical reasoning for appro-
priate selection of patients who are most likely to benefit 
from magnetic hyperthermia as adjuvant therapy with RT 
in the management of gliomas.
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